Search Results

You are looking at 121 - 130 of 595 items for :

  • "surveillance" x
Clear All
Full access

footnote “k” was added: “Ta verrucous carcinoma is by definition a well-differentiated tumor and would require surveillance alone of inguinal lymph nodes.” Footnote “n” was added: “A modified/superficial inguinal dissection with intraoperative frozen

Full access

James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Anthony Victor D'Amico, Brian J. Davis, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric M. Horwitz, Michael Hurwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Joshua J. Meeks, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ted A. Skolarus, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Dorothy A. Shead and Deborah A. Freedman-Cass

figures. Risk Stratification Management approaches for locoregional prostate cancer include surgery, radiotherapy, active surveillance (actively monitoring disease, with curative-intent intervention if cancer progresses), observation (monitoring

Full access

Benjamin L. Franc, Timothy P. Copeland, Robert Thombley, Miran Park, Ben Marafino, Mitzi L. Dean, W. John Boscardin, Hope S. Rugo, David Seidenwurm, Bhupinder Sharma, Stephen R. Johnston and R. Adams Dudley

breast cancer diagnosed by age 50 years, receive dedicated breast MRI annually. 2 ASCO and NCCN have issued guidelines stating that, after initial treatment, surveillance for recurrence in patients with stage I–III breast cancer should include periodic

Full access

Heather Hampel

their relatives to undergo genetic counseling and testing to learn if they too are at increased risk for cancer and could benefit from intensive cancer surveillance. The costs of screening can be offset by the benefits of cancer prevention in the patient

Full access

Mary Ann Morgan and Crystal S. Denlinger

-management; (2) surveillance for cancer spread, recurrence, or second cancers, along with monitoring for late effects, including psychological consequences; (3) interventions for these effects; and (4) coordination between the oncology providers and PCPs. 5

Full access

Christina A. Minami and Karl Y. Bilimoria

present, with information from more than 1,500 CoC-accredited hospitals throughout the United States and Puerto Rico. The NCDB is a facility-based clinical surveillance resource that is also meant to be used in quality improvement (QI), allowing hospitals

Full access

Randall W. Burt, James S. Barthel, Kelli Bullard Dunn, Donald S. David, Ernesto Drelichman, James M. Ford, Francis M. Giardiello, Stephen B. Gruber, Amy L. Halverson, Stanley R. Hamilton, Mohammad K. Ismail, Kory Jasperson, Audrey J. Lazenby, Patrick M. Lynch, Edward W. Martin Jr., Robert J. Mayer, Reid M. Ness, Dawn Provenzale, M. Sambasiva Rao, Moshe Shike, Gideon Steinbach, Jonathan P. Terdiman and David Weinberg

reduction persists after colonoscopy. They compared incidence of CRC among patients in the surveillance cohort with that in the general population. A negative colonoscopy was associated with a standardized incidence ratio of 0.28 (95% CI, 0.09–0.65) at 10

Full access

of capecitabine + oxaliplatin was added as an option in adjuvant therapy with a category 2A designation. Footnote “j” was clarified by adding “exclusive of those cancers that are MSI-H” to grade 3-4. Surveillance Chest

Full access

Amit G. Singal, Akbar K. Waljee, Nishant Patel, Emerson Y. Chen, Jasmin A. Tiro, Jorge A. Marrero and Adam C. Yopp

only available for patients diagnosed at an early stage. 2 Surveillance at 6-month intervals is recommended in patients with cirrhosis to detect HCC at an early stage. 3 Despite the availability of efficacious surveillance tests, only 40% of patients

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer and Rashmi Kumar

Guidelines provide a framework for follow-up of patients undergoing surveillance of a small renal mass, those who underwent surgery or ablative therapy of a primary RCC, and those undergoing NCCN Guidelines Insights : Kidney Cancer, Version 3